MedPath

Co-creating and evaluating an online self-help treatment (iSelf-help) for people with persistent pai

Not Applicable
Recruiting
Conditions
Persistent non-cancer pain
persistent primary pain
persistent secondary pain
Anaesthesiology - Pain management
Registration Number
ACTRN12619000771156
Lead Sponsor
Prof Leigh Hale
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
180
Inclusion Criteria

People with persistent, non-cancer pain referred for pain management at a tertiary pain management service from the lower half of the North Island and the upper half of the South Island, New Zealand,

Participants with any of the following persistent pain conditions will be included in the study:
•Persistent primary pain,
•Persistent musculoskeletal pain
•Persistent posttraumatic and postsurgical pain
•Persistent neuropathic pain,
•Persistent headache and orofacial pain
•Persistent visceral pain.

Inclusion criteria
(1)Adults with persistent non-cancer pain (defined above) aged 18 years and older,
(2)With daily access to a computer/smartphone at home, workplace or in a public location,
(3) Currently not experiencing any significant uncontrolled mental health condition
(4)Able to provide written informed consent.

We will provide internet subscription for the study period for those without internet access.

Exclusion Criteria

(1) Participants with severe depression defined as >20 from the 7 items of Depression subscale of Depression, Anxiety, Stress Scale (DASS-21)53 and based on clinical evaluation by CCDHB pain management service.
(2) Primary cancer-related pain
(3) Planned surgical intervention for pain
(4) Concurrent participation in an additional multi-disciplinary group based pain management programme

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Pain related disability using modified Roland Morris Disability Questionnaire (RMDQ)[Baseline. immediately after intervention (after 12 weeks), and 3 and 6 months post intervention.]
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath